Join our community of traders FOR FREE!

  • Learn
  • Improve yourself
  • Get Rewards
Learn More

Pfizer Inc, the leading US drugmaker, posted quarterly earnings today, revealing steady revenue and profit, with declining sales for major divisions and climbing R&D expenses. Full-year outlook was slightly lowered, but still relatively positive.

The New York-based companys Q2 revenue was logged at $12.773 billion, down 2% from last year. Net income dropped 77% to $2.912 billion, or $0.45 per share, as last years Q2 profit is skewed by the sale of Pfizers animal health unit for about $10 billion. Excluding the divestment, net income rose 3.57%

“I am pleased with our operating performance to date. Our recently launched products continued to gain traction during the quarter,” Ian Read, Chairman and Chief Executive Officer, stated. “I continue to see Pfizer as well positioned to effectively execute on our strategy to further strengthen each of our businesses on a global basis and deliver value to all of our stakeholders.”

Revenue from established and innovative pharmaceuticals, which account for 51% and 28% of total revenue, respectively, dropped by about 5% and 6%, respectively. The drop is attributed to several patents expiring, allowing for stiff competition for a number of drugs.

Vaccines, consumer healthcare and oncology medicines, however, added between 14% and 16% from a year ago.

Meanwhile, Pfizers expenses increased by 4% to $7.520 billion, with research and development adding a good 13% on an annual basis to $1.714 billion.

Also, Pfizer lowered its full-year revenue projection to $48.7 – $50.7 billion, down from $49.2 – $51.2 billion, with focus on more patents expiring, which could hurt performance.

The profit outlook “reflects our financial flexibility and confidence in the business going forward,” Chief Financial Officer Frank DAmelio said in the news release.

Pfizer recently unsuccessfully attempted to acquire UK-based AstraZeneca for a reported $120 billion, in a bid to lower its tax rate by a so-called tax inversion move, in which it would redomicile in the UK, where corporate taxes are 21%, compared to the US 35%.

A number of other US pharmaceutical companies already completed tax inversions, including Mylan and AbbVie, while Hospira also considers the option.

Pfizer Inc was up 0.30% to trade at $30.19 per share at 14:37 GMT, giving the company a market capitalization of $191.80 billion. According to the Financial Times, 16 analysts offering 12 month price targets for Pfizer Inc. have a median target of $34.50, with a high estimate of $41.00 and a low estimate of $30.00. The median estimate represents a 14.62% increase from the last price of $30.10.

TradingPedia.com is a financial media specialized in providing daily news and education covering Forex, equities and commodities. Our academies for traders cover Forex, Price Action and Social Trading.

Related News

  • Gold trading outlook: futures hold near 7-week highs on China fearsGold trading outlook: futures hold near 7-week highs on China fears Gold eased in early European trading on Monday but held close to Fridays 7-week high as fears over a slowing Chinese economy forced investors away from riskier assets, sending Asian equities tumbling and spurring demand for safe haven […]
  • Reserve Bank of India leaves policy rate on hold as expectedReserve Bank of India leaves policy rate on hold as expected The Reserve Bank of India left its key repo rate at 6.5% for the seventh straight policy meeting in April, in line with market expectations.The RBI decision came amid persistent price pressures. India's annual inflation rate was […]
  • SAIC wins $444 million Space Force contractSAIC wins $444 million Space Force contract Science Applications International Corp (NASDAQ: SAIC) said this week it had received a $444 million contract to support Digital Transformation, Acquisition, Modernization and Modification for the US Space Force's Space Systems Command and […]
  • Boeing shares gain the most in two weeks on Friday, a third 737 MAX jetliner delayed in deliveryBoeing shares gain the most in two weeks on Friday, a third 737 MAX jetliner delayed in delivery The delivery of a third 737 MAX jet to Norwegian Air Shuttle, scheduled for the upcoming week, had been postponed due to a technical issue, Boeing Company (BA) said on June 2nd.Boeing shares registered their largest daily surge since […]
  • Forex Market: EUR/CHF daily trading forecastForex Market: EUR/CHF daily trading forecast Yesterday’s trade saw EUR/CHF within the range of 1.2067-1.2115. The pair closed at 1.2090, gaining 0.03% on a daily basis.At 6:18 GMT today EUR/CHF was down 0.01% for the day to trade at 1.2088. The pair touched a daily low at 1.2084 […]
  • U.S. crude oil reserves increaseU.S. crude oil reserves increase U.S. Crude Oil Inventories increased by 3 million barrels last week and reached 397,6 million barrels, showed the U.S. Energy Information Administrations report on Thursday. Forecast was for a decline of 600 000 barrels to 393,8 million. Crude […]